The UK's National Institute for Health and Care Excellence (NICE) has given the green light for a groundbreaking new drug called teplizumab. This innovative treatment aims to slow down or even put off the onset of type 1 diabetes, offering hope to thousands of families affected by this condition.
Teplizumab targets the immune system, helping to protect the insulin-producing cells in the pancreas from being destroyed. It works by injecting a short course of intravenous infusions, and is recommended for children aged eight and over who are at high risk of developing type 1 diabetes. This is typically identified when two or more autoantibodies associated with the condition are present, along with abnormal blood glucose levels.
Studies have shown that teplizumab can delay the diagnosis of type 1 diabetes by around three years on average – in some cases, even longer. This extra time could significantly improve quality of life for individuals and their families, reducing the immediate burden of managing the condition, and potentially lowering the risk of serious complications like diabetic ketoacidosis at diagnosis.
With NICE's approval, the NHS will now fund teplizumab, making it available to those who meet the eligibility criteria through a managed access agreement. This approach allows for further data collection on its long-term effectiveness and impact in real-world settings.
Type 1 diabetes affects around 400,000 people in the UK, with approximately 29,000 children and young people living with the condition. Unfortunately, it is an irreversible autoimmune disease that cannot be prevented by lifestyle changes – making this new treatment a crucial step forward.
While teplizumab won't prevent type 1 diabetes, delaying its onset gives individuals and their families valuable time to prepare for the challenges ahead. It also opens up more opportunities for research into potential future treatments or even a cure. If you're concerned about your risk of developing type 1 diabetes or that of a family member, speak to your GP or diabetes specialist team to discuss eligibility for screening and potential treatment options.